Neoadjuvant treatment for resectable pancreatic adenocarcinoma: What is the best protocol?

Fuyuhiko Motoi, Michiaki Unno

研究成果: Review article

3 被引用数 (Scopus)

抄録

Although upfront surgery has been the gold standard for pancreatic adenocarcinoma that is planned for resection, it should be compared with the alternative strategy of neoadjuvant therapy. Despite the many reports of the efficacy of neoadjuvant therapy, most of them were not comparative. Recently Prep-02/JSAP05 study clearly demonstrated the significant survival benefit of neoadjuvant chemotherapy over upfront surgery for pancreatic adenocarcinoma that is planned for resection. These findings opened a new chapter of neoadjuvant therapy. Ongoing trials are expected to confirm the evidence. This review summarizes the past, present, and future perspectives of neoadjuvant therapy and its optimization.

本文言語English
ページ(範囲)100-108
ページ数9
ジャーナルAnnals of Gastroenterological Surgery
4
2
DOI
出版ステータスPublished - 2020 3 1

ASJC Scopus subject areas

  • Gastroenterology
  • Surgery

フィンガープリント 「Neoadjuvant treatment for resectable pancreatic adenocarcinoma: What is the best protocol?」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル